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STATE-OF-THE-ART PAPER
AND COMMENTARYSTATE-OF-THE-ART PAPER AND COMMENTARYA Novel Paradigm for Heart Failure With Preserved Ejection Fraction: Comorbidities
Drive Myocardial Dysfunction and Remodeling Through Coronary Microvascular
Endothelial Inﬂammation263Walter J. Paulus, Carsten Tschöpe
Paulus and Tschöpe propose a new paradigm to explain heart failure with preserved ejection
fraction. The new paradigm presumes the following sequence of events: 1) comorbidities such
as overweight/obesity, diabetes mellitus, chronic obstructive pulmonary disease, and salt-
sensitive hypertension induce a systemic proinﬂammatory state; 2) this proinﬂammatory state
causes coronary microvascular endothelial inﬂammation; 3) coronary microvascular
endothelial inﬂammation reduces nitric oxide bioavailability, cyclic guanosine
monophosphate content, and protein kinase G (PKG) activity in adjacent cardiomyocytes;
4) low PKG activity favors hypertrophy development and raises resting tension because of
hypophosphorylation of titin; 5) both stiff cardiomyocytes and interstitial ﬁbrosis contribute
to high diastolic left ventricular stiffness and heart failure development.
Commentary: Akshay S. Desai, p. 272CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYSame-Day Discharge After Percutaneous Coronary Intervention: A Meta-Analysis 275
Kimberly M. Brayton, Vishal G. Patel, Christopher Stave, James A. de Lemos, Dharam J. Kumbhani
Brayton and colleagues performed a meta-analysis of 37 studies to assess the safety of same-
day discharge after percutaneous coronary intervention (PCI). Data from 12,803 patients in
37 studies were collated, including 7 randomized controlled trials (RCT) and 30
observational studies. In the RCTs, no difference was seen between same-day discharge and
routine overnight observation with regard to the combined endpoint of death, myocardial
infarction (MI), or target lesion revascularization (TLR) or for major bleeding/vascular
complications. In observational studies, the primary outcome of death/MI/TLR occurred at a
pooled rate of 1.00%, and major bleeding/vascular complications occurred at a pooled rate of
0.68%. In selected patients undergoing PCI, same-day discharge appears to be as safe as
overnight observation.(continued on page A-27)
JULY 23, 2013 (continued) A-27ACUTE CORONARY SYNDROMESReduction of Stent Thrombosis in Patients With Acute Coronary Syndrome Treated
With Rivaroxaban in ATLAS ACS 2-TIMI 51286C. Michael Gibson, Anjan K. Chakrabarti, Jessica Mega, Christophe Bode, Jean-Pierre Bassand,
Freek W. A. Verheugt, Deepak L. Bhatt, Shinya Goto, Marc Cohen, Satishkumar Mohanavelu,
Paul Burton, Gregg Stone, Eugene Braunwald, for the ATLAS-ACS 2-TIMI 51 Investigators
ATLAS ACS 2-TIMI 51 randomly assigned over 15,000 patients with a recent acute
coronary syndrome (ACS) to either 2.5 mg or 5 mg of rivaroxaban twice daily or placebo.
Among subjects who had a stent placed prior to or at the time of the index event, rivaroxaban
signiﬁcantly reduced Academic Research Consortium (ARC) deﬁnite, probable, or possible
stent thrombosis in the pooled (2.9% vs. 2.3%) and the 2.5 mg twice daily (2.9% vs. 2.2%)
treatment groups when compared to placebo. Subjects who received dual antiplatelet therapy
(DAPT) beneﬁtted from rivaroxaban with lower rates of both stent thrombosis and mortality
for the 2.5 mg twice daily dose. These results suggest that addition of rivaroxaban to DAPT
can further reduce the risk of stent thrombosis and death.CARDIOMETABOLIC RISKHigh Intestinal Cholesterol Absorption Is Associated With Cardiovascular Disease
and Risk Alleles in ABCG8 and ABO: Evidence From the LURIC and YFS Cohorts
and From a Meta-Analysis291Günther Silbernagel, M. John Chapman, Bernd Genser, Marcus E. Kleber, Günter Fauler,
Hubert Scharnagl, Tanja B. Grammer, Bernhard O. Boehm, Kari-Matti Mäkelä, Mika Kähönen,
Rafael Carmena, Ernst R. Rietzschel, Eric Bruckert, John E. Deanﬁeld, Tatu A. Miettinen,
Olli T. Raitakari, Terho Lehtimäki, Winfried März
Plant sterol-enriched foods help to lower cholesterol, but high circulating levels of plant
sterols have also been associated with cardiac risk. Silbernagel and colleagues studied whether
high intestinal cholesterol absorption may link genetic variants in ATP-binding cassette
transporters G5 and G8 (ABCG5/8) to increased cardiac risk. The cholestanol-
to-cholesterol ratio (CR) was used as an estimate of cholesterol absorption. Review of 2
population-based studies conﬁrmed a link between ABC G5 and G8 variants with the CR. A
meta-analysis, including 6 studies and 4,362 individuals, showed that CR was signiﬁcantly
increased in individuals with cardiovascular disease. These results suggest that increased
intestinal cholesterol absorption mediates the increased cardiac risk seen in certain ABC
genetic variants rather than high levels of plant sterols.(continued on page A-28)
JULY 23, 2013 (continued) A-28HEART RHYTHM DISORDERSTreatment of Obstructive Sleep Apnea Reduces the Risk of Atrial Fibrillation
Recurrence Following Catheter Ablation300Adam S. Fein, Alexei Shvilkin, Dhaval Shah, Charles I. Haffajee, Saumya Das, Kapil Kumar,
Daniel B. Kramer, Peter J. Zimetbaum, Alfred E. Buxton, Mark E. Josephson, Elad Anter
Fein and partners examined the effect of continuous positive airway pressure (CPAP) therapy
on atrial ﬁbrillation (AF) recurrence in patients with obstructive sleep apnea (OSA) who
underwent pulmonary vein isolation (PVI). Among 426 patients who underwent PVI, 62
patients had a polysomnography-conﬁrmed diagnosis of OSA. Half of these patients were
compliant with CPAP therapy. CPAP therapy resulted in higher AF-free survival rate (72%
vs. 37%) after PVI. The AF recurrence rate in CPAP-treated patients was similar to a
matched group of patients without OSA, while the rate in OSA patients not using CPAP
was similar to AF patients who did not undergo PVI. These results show that treating OSA
with CPAP therapy can signiﬁcantly increase the likelihood of success with PVI.
Editorial Comment: Bernard Belhassen, p. 306CARDIAC IMAGINGImpact of an Automated Multimodality Point-of-Order Decision Support Tool on Rates
of Appropriate Testing and Clinical Decision Making for Individuals With Suspected
Coronary Artery Disease: A Prospective Multicenter Study308Fay Y. Lin, Allison M. Dunning, Jagat Narula, Leslee J. Shaw, Heidi Gransar, Daniel S. Berman,
James K. Min
Lin and colleagues performed a prospective, multicenter cohort study evaluating the effects of
a Point-of-Order Decision Support Tool (DST) on physicians who order coronary artery
disease imaging tests. The DST was used to determine the appropriateness of the ordered
test based on published appropriate use criteria. A total of 100 physicians used the DST for
472 patients. The number of tests classiﬁed as appropriate increased from 49% to 61% when
comparing the ﬁrst 2 months with the last 2 months while inappropriate tests decreased from
22% to 6%. There were also higher rates of intended changes in medical therapy based on
imaging results. The authors propose that use of a DST may reduce the need for prior
authorization of cardiac imaging studies.(continued on page A-29)
JULY 23, 2013 (continued) A-29HEART VALVE DISEASE4-Year Results of a Randomized Controlled Trial of Percutaneous Repair Versus
Surgery for Mitral Regurgitation317Laura Mauri, Elyse Foster, Donald D. Glower, Patricia Apruzzese, Joseph M. Massaro,
Howard C. Herrmann, James Hermiller, William Gray, Andrew Wang, Wesley R. Pedersen,
Tanvir Bajwa, John Lasala, Reginald Low, Paul Grayburn, Ted Feldman, for the EVEREST II
Investigators
In the EVEREST II trial, subjects with 3+ or 4+ mitral regurgitation (MR) in heart valve
were randomized to either surgery or percutaneous repair with the MitraClip device (Abbott,
Menlo Park, California). For this article, Mauri and colleagues report the extended follow-up
from the EVEREST II trial. At 4 years, there were no statistical differences in the rates of
death or 3+ or 4+ MR in heart valve, but there was a much higher rate of surgery for mitral
valve dysfunction (25% vs. 5.5%) with initial percutaneous repair. The vast majority of these
surgeries occurred within the ﬁrst year suggesting that when the percutaneous repair is
initially successful, the results are durable.BIOMARKERSAggregate Risk Score Based on Markers of Inﬂammation, Cell Stress, and
Coagulation Is an Independent Predictor of Adverse Cardiovascular Outcomes329Danny J. Eapen, Pankaj Manocha, Riyaz S. Patel, Muhammad Hammadah, Emir Veledar,
Christina Wassel, Ravi A. Nanjundappa, Sergey Sikora, Dylan Malayter, Peter W. F. Wilson,
Laurence Sperling, Arshed A. Quyyumi, Stephen E. Epstein
Eapen and colleagues hypothesized that an aggregate risk score comprising biomarkers from
inﬂammatory, coagulation, and cellular stress pathways would predict the subsequent risk of
death or myocardial infarction (MI) in patients with conﬁrmed or suspected coronary artery
disease. Serum levels of high-sensitivity C-reactive protein (CRP), ﬁbrin degradation
products (FDP), and heat shock protein 70 (HSP70), were measured in 3,415 consecutive
patients undergoing cardiac catheterization and followed for a median 2.3 years. An aggregate
biomarker score between 0 and 3 was calculated based on the number of elevated biomarkers.
Compared to the group with 0 score, the risk for all-cause death and MI were 1.83, 3.46, and
4.99 times higher for those with scores of 1, 2, and 3, respectively. Combining biomarkers
from 3 different pathways may improve risk stratiﬁcation.
Editorial Comment: Michele Emdin, Luigi Emilio Pastormerlo, Claudio Passino, p. 338(continued on page A-30)
JULY 23, 2013 (continued) A-30PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCHProvocation of an Autoimmune Response to Cardiac Voltage–Gated Sodium Channel
NaV1.5 Induces Cardiac Conduction Defects in Rats340Sevil Korkmaz, Edgar Zitron, Anna Bangert, Claudia Seyler, Shiliang Li, Peter Hegedüs,
Daniel Scherer, Jin Li, Thomas Fink, Patrick A. Schweizer, Evangelos Giannitsis, Matthias Karck,
Gábor Szabó, Hugo A. Katus, Ziya Kaya
Korkmaz and colleagues tested the hypothesis that inducing an autoimmune response against
the cardiac voltage-gated sodium channel (NaV1.5) would induce arrhythmias. Rats were
immunized with a peptide sequence derived from NaV1.5. NaV1.5-immunized animals
showed signiﬁcantly prolonged PR intervals and signiﬁcant episodes of third-degree
atrioventricular (AV) and sinoatrial block. Immunization had no effect on cardiac function.
Further studies showed that humans with idiopathic AV block had autoantibodies against
NaV1.5 while healthy controls did not. These results suggest that an autoimmune reaction to
NaV1.5 may underlay some cases of AV block.
